-
-
-
-
-
-
-
Crinetics Pharmaceuticals (CRNX) Reports paltusotine met Primary and All Secondary Endpoints
-
-
-
-
-
-
-
Natera (NTRA) announces phase III trial of signatera to treat stage II colorectal cancer in France
-
-
-
-
-
-
-
Cybin (CYBN) Initiates Phase 2 Proof-of-Concept Study of CYB004
-
-
-
-
-
-
-
Madrigal Pharma (MDGL): FDA Approves rezdiffra
-
-
-
-
-
-
-
Mirum Pharmaceuticals (MIRM) Announces FDA Approval of LIVMARLI
-
-
-
-
-
-
-
CalciMedica (CALC) Presents Data from Preclinical Studies of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference
-
-
-
-
-
-
-
Unicycive Therapeutics (UNCY) Delivers Both an Oral and Poster Presentation on UNI-494 at the AKI and CRRT Conference
-
66,455 total articles have been posted to this category.
Sign-up to StreetInsider.com Premium
to see all today's market moving FDA reports.